Non-small Cell Lung Cancer (NSCLC) treatment has evolved from a chemotherapy-dominated approach to a biomarker-driven paradigm, enabled by the identification of multiple actionable alterations, including the EGFR signaling pathway, ALK, BRAF, RET, NTRK, HER2, KRAS, ROS1, and MET alterations. This shift has expanded targeted NSCLC treatment options and improved outcomes; however, resistance and suboptimal durability remain persistent challenges. Biomarker testing is crucial for all patients with advanced NSCLC to identify actionable genetic mutations (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS) and protein expression (PD-L1).
It is recommended to use comprehensive...
